查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579714

SNP基因型鉴定和分析的全球市场

SNP Genotyping and Analysis
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 173 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球 SNP基因型鉴定和分析市场将达到 591 亿美元

全球SNP基因型鉴定和分析市场预计2023年为178亿美元，预计2030年将达到591亿美元，2023-2030年分析期间复合年增长率为18.7%。透过微阵列和基因晶片进行 SNP基因型鉴定是本报告分析的细分领域之一，预计复合年增长率为 22.2%，到分析期结束时将达到 229 亿美元。在分析期间，Taqman 等位基因歧视领域的复合年增长率估计为 17.9%。

美国市场预计51亿美元，中国预计复合年增长率18.0%

到 2023 年，美国SNP基因型鉴定和分析市场预计将达到 51 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达90亿美元，2023-2030年分析期间复合年增长率为18.0%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 16.9% 和 15.1%。在欧洲，德国的复合年增长率预计约为 12.3%。

全球 SNP基因型鉴定和分析市场 - 主要趋势和驱动因素总结

什么是 SNP基因型鉴定和分析？

SNP基因型鉴定和分析是指识别和研究单核苷酸多态性 (SNP)（发生在基因组特定位置的单碱基变异）的过程。这些遗传变异是影响个体对疾病、药物和环境因素反应的重要指标。透过分析 SNP，研究人员可以揭示遗传变异与特定性状或状况之间的关联，从而深入了解遗传倾向和各种疾病的分子机制。 SNP基因型鉴定广泛应用于基因组学研究、药物基因体学、农业生物技术和精准医学等领域，在这些领域，了解遗传变异可以开发标靶治疗、个人化治疗计划和作物，从而改良牲畜品种。

SNP基因型鉴定和分析在全球范围内的普及正在改变基因研究和医疗保健领域，能够更准确、更有效地识别与复杂性状和疾病相关的遗传变异。 SNP 是人类基因组中最常见的遗传变异，它们的分析为研究遗传多样性及其对生物功能的影响提供了一种经济有效的高通量方法。在医疗保健领域，SNP基因型鉴定在精准医疗中发挥重要作用，它可以让临床医生预测个体对药物的反应、识别疾病的危险因子并根据遗传图谱制定治疗方案。 SNP基因型鉴定在疾病相关研究中的应用已导致癌症、糖尿病、心血管疾病和神经系统疾病等疾病的遗传风险因素的识别。随着个人化医疗和基因组研究的需求不断增长，SNP基因型鉴定和分析正成为增进我们对人类健康和疾病了解的重要工具。

技术进步如何影响 SNP基因型鉴定和分析的开发和应用？

技术进步极大地提高了 SNP基因型鉴定和分析的效率、准确性和范围，使研究人员和临床医生能够更深入地了解遗传变异及其对健康和疾病的影响。该领域最重要的创新之一是高通量基因分型平台的开发，例如微阵列和次世代定序（NGS）技术。微阵列使研究人员能够同时分析数千个 SNP，从而能够进行全基因组关联研究 (GWAS)，大规模识别遗传变异和表型性状之间的相关性。微阵列技术因其成本效益、速度和提供高品质资料的能力而成为基因型鉴定的标准工具。此外，NGS 技术的进步现在使研究人员能够以无与伦比的深度和精度对整个基因组或目标区域进行测序，使研究人员能够检测传统基因型鉴定方法无法捕获的罕见 SNP 和结构变异。

另一个重大技术发展是生物资讯学和资料分析工具的整合。这些对于处理和解释 SNP基因型鉴定和定序产生的大量资料至关重要。生物资讯软体和演算法用于识别 SNP、预测其功能效应并评估与疾病和性状的关联。这些工具使研究人员能够执行复杂的统计分析、视觉化遗传资料并整合多种资料，例如基因表现和表观遗传修饰，从而全面了解遗传对生物过程的影响。机器学习和人工智慧也被应用于SNP分析，以根据遗传资料识别模式并预测预后，为发现生物标记和治疗标靶提供新的机会。

此外，单细胞基因型鉴定和数位 PCR (dPCR) 的进步正在将 SNP 分析的应用范围扩大到癌症研究、生殖医学和发育生物学等领域。单细胞基因型鉴定使研究人员能够分析单一细胞层面的遗传变异，从而深入了解复杂组织和肿瘤中的细胞异质性和克隆进化。这项技术在肿瘤学中特别有价值，了解肿瘤内的遗传变异可以为治疗策略提供资讯并改善患者的治疗结果。同样，dPCR 可以以高灵敏度和特异性检测低频 SNP 和拷贝数变异，使其成为液态切片、产前检测和病原体检测等应用的理想选择。这些技术进步不仅提高了KEYWORD的功能，而且拓宽了其应用范围，使其成为研究和临床应用的多功能工具。

哪些因素推动 SNP基因型鉴定和分析在不同产业和地区的采用？

SNP基因型鉴定和分析的采用是由几个重要因素推动的，包括遗传性疾病盛行率的增加、对个人化医疗的需求不断增加以及对农业生物技术的日益关注。关键驱动因素之一是遗传疾病的日益普及以及对改善诊断和治疗解决方案的需求。随着我们对疾病遗传基础的了解不断加深，越来越需要准确有效地检测导致疾病感受性和药物反应性的遗传变异的方法。 SNP基因型鉴定为识别这些突变提供了宝贵的工具，使研究人员和临床医生能够开发更有效的诊断测试和治疗策略。这种趋势在肿瘤学中尤其明显，其中 SNP 分析用于识别与癌症相关的突变、确定治疗策略并监测疾病进展。

推动 SNP基因型鉴定采用的另一个重要因素是对个人化医疗的需求不断增长。精准医学旨在根据遗传、环境和生活方式因素为个别患者量身定制治疗方案。 SNP基因型鉴定在这种方法中发挥重要作用，它可以深入了解遗传变异如何影响药物代谢、功效和安全性。药物基因体学是个人化医疗的关键组成部分，它利用 SNP 分析来识别影响药物反应的遗传标记，使临床医生能够为每位患者选择最合适的治疗方法和剂量。这种个人化方法不仅可以改善治疗结果，还可以降低药物不良反应的风险，并提高患者的安全性和满意度。 SNP基因型鉴定在药物基因体学中的使用越来越多，正在推动其在医疗保健环境中的采用，特别是在北美和欧洲等发达地区，精准医疗倡议正在蓬勃发展。

此外，对农业生物技术的日益关注影响了 SNP基因型鉴定在作物和牲畜育种中的采用。在农业中，SNP 分析用于识别与抗病性、耐旱性和产量等所需性状相关的遗传标记。透过选择这些标记，育种者可以开发出更适合不断变化的环境条件和市场需求的改良作物和牲畜品种。 SNP基因型鉴定在植物和动物基因组研究中也发挥着重要作用，用于绘製基因图谱、研究遗传多样性以及了解复杂性状的遗传基础。这项技术有助于加速永续农业实践的发展并改善粮食安全，特别是在农业是经济重要组成部分的地区，例如亚太和拉丁美洲。由于这些因素持续影响基因研究和精准育种的需求，SNP基因型鉴定的采用预计将扩展到不同领域和地区。

谁在推动全球 SNP基因型鉴定和分析市场的成长？

全球 SNP基因型鉴定和分析市场的成长受到多种因素的推动，例如基因组研究投资的增加、遗传疾病发病率的上升以及基因型鉴定技术的进步。关键的成长要素之一是政府、学术机构和私人公司对基因组研究的投资增加。随着基因组研究在了解人类健康和疾病方面的重要性不断增强，我们致力于资助旨在绘製遗传变异图谱、识别与疾病相关的 SNP 以及开发新治疗方法的计划和倡议，这引起了越来越多的关注。人类基因组计划、千基因组计划和英国生物银行等重大倡议正在产生大量遗传资料，为进一步研究奠定了基础，并推动了对先进 SNP基因型鉴定和分析工具的需求。基因组学研究资金的增加正在为市场扩张创造机会，特别是在北美和欧洲等正在进行大规模基因组研究的已开发地区。

市场成长的另一个重要驱动因素是遗传疾病盛行率的上升以及对改善诊断和治疗解决方案的需求。囊肿纤维化、镰状细胞性贫血和亨廷顿病等遗传性疾病通常是由特定的基因突变引起的，这些突变可以透过 SNP基因型鉴定来识别。随着人们对这些疾病认识的提高和诊断技术的进步，对提供准确和早期诊断的基因检测服务的需求不断增加。 SNP基因型鉴定提供了一种可靠的方法来识别遗传变异和评估疾病风险，推动其在临床实践中的采用。遗传疾病的盛行率不断上升，特别是在亚太和中东等地区，对基因检测和个人化医疗的需求迅速增加。

此外，基因型鉴定技术的进步正在支持 SNP基因型鉴定和分析市场的成长。 NGS和微阵列等高通量平台的发展使研究人员能够以低成本和高精度进行大规模基因型鉴定研究。这些技术也被用于开发 SNP 分析的新应用，例如多基因风险评分，根据多个 SNP 的累积效应评估个体常见疾病的遗传风险。高通量基因型鉴定和复杂遗传资料分析的可用性将 SNP基因型鉴定的范围扩展到传统用途之外，为研究和临床应用创造了新的机会。此外，商业基因型鉴定服务和直接面向消费者的基因检测套组的可用性不断增加，使更多人能够更轻鬆地进行 SNP 分析，从而进一步支持市场成长。

此外，对精准医学的日益关注以及基因组资料越来越多地融入临床实践也影响 SNP基因型鉴定和分析市场的成长。精准医学倡议，例如美国的精准医学倡议和欧洲 1+000 万基因组倡议，为临床决策倡议，我们推进遗传资料的使用，以改善患者的治疗结果。这些倡议正在推动 SNP基因型鉴定在医疗保健环境中的采用，以指导治疗决策、预测疾病风险并确定潜在的药物标靶。随着这些因素继续塑造全球基因组学格局，在研究投资增加、技术进步以及对个人化医疗和基因检测解决方案的需求增加的推动下，市场格局预计将出现强劲增长。

受访企业范例（42家知名企业）

  • Affymetrix, Inc.
  • F. Hoffmann-La Roche AG
  • Fluidigm Corporation
  • Illumina, Inc.
  • Life Technologies Corporation
  • Sequenom, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP16798

Global SNP Genotyping and Analysis Market to Reach US$59.1 Billion by 2030

The global market for SNP Genotyping and Analysis estimated at US$17.8 Billion in the year 2023, is expected to reach US$59.1 Billion by 2030, growing at a CAGR of 18.7% over the analysis period 2023-2030. SNP Genotyping by Microarrays and GeneChips, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$22.9 Billion by the end of the analysis period. Growth in the Taqman Allelic Discrimination segment is estimated at 17.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 18.0% CAGR

The SNP Genotyping and Analysis market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.0 Billion by the year 2030 trailing a CAGR of 18.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.9% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.3% CAGR.

Global SNP Genotyping and Analysis Market - Key Trends & Drivers Summarized

What Is SNP Genotyping and Analysis and Why Is It Crucial for Advancing Genomic Research and Precision Medicine?

SNP genotyping and analysis refers to the process of identifying and examining single nucleotide polymorphisms (SNPs)—variations in a single nucleotide that occur at a specific position in the genome. These genetic variations are crucial markers that can influence how individuals respond to diseases, medications, and environmental factors. By analyzing SNPs, researchers can uncover associations between genetic variations and specific traits or conditions, providing insights into genetic predispositions and the molecular mechanisms underlying various diseases. SNP genotyping is widely used in diverse fields such as genomic research, pharmacogenomics, agricultural biotechnology, and precision medicine, where understanding genetic variation can lead to the development of targeted therapies, personalized treatment plans, and improved crop and livestock breeding.

The global adoption of SNP genotyping and analysis is transforming the fields of genetic research and healthcare by enabling more accurate and efficient identification of genetic variants associated with complex traits and diseases. SNPs are the most common type of genetic variation in the human genome, and their analysis provides a cost-effective and high-throughput means of studying genetic diversity and its effects on biological functions. In healthcare, SNP genotyping plays a pivotal role in precision medicine by allowing clinicians to predict individual responses to drugs, identify risk factors for diseases, and tailor treatments based on genetic profiles. The use of SNP genotyping in disease association studies has led to the identification of genetic risk factors for conditions such as cancer, diabetes, cardiovascular diseases, and neurological disorders. As the demand for personalized medicine and genomic research continues to grow, SNP genotyping and analysis are becoming essential tools for advancing our understanding of human health and disease.

How Are Technological Advancements Shaping the Development and Application of SNP Genotyping and Analysis?

Technological advancements are significantly enhancing the efficiency, accuracy, and scope of SNP genotyping and analysis, enabling researchers and clinicians to gain deeper insights into genetic variations and their impact on health and disease. One of the most significant innovations in this field is the development of high-throughput genotyping platforms, such as microarrays and next-generation sequencing (NGS) technologies. Microarrays allow researchers to analyze thousands of SNPs simultaneously, making it possible to conduct genome-wide association studies (GWAS) that identify correlations between genetic variants and phenotypic traits on a large scale. Microarray technology has become a standard tool for genotyping due to its cost-effectiveness, speed, and ability to provide high-quality data. Additionally, advances in NGS technology are enabling researchers to sequence entire genomes or targeted regions with unparalleled depth and accuracy, allowing for the detection of rare SNPs and structural variants that are not captured by traditional genotyping methods.

Another key technological development is the integration of bioinformatics and data analysis tools, which are essential for processing and interpreting the vast amounts of data generated by SNP genotyping and sequencing. Bioinformatics software and algorithms are being used to identify SNPs, predict their functional effects, and assess their association with diseases or traits. These tools enable researchers to perform complex statistical analyses, visualize genetic data, and integrate multiple data types, such as gene expression and epigenetic modifications, to gain a holistic understanding of genetic influences on biological processes. Machine learning and AI are also being applied to SNP analysis to identify patterns and predict outcomes based on genetic data, providing new opportunities for discovering biomarkers and therapeutic targets.

Furthermore, advancements in single-cell genotyping and digital PCR (dPCR) are expanding the applications of SNP analysis to areas such as cancer research, reproductive health, and developmental biology. Single-cell genotyping allows researchers to analyze genetic variations at the level of individual cells, providing insights into cellular heterogeneity and clonal evolution in complex tissues or tumors. This technology is particularly valuable in oncology, where understanding the genetic diversity within a tumor can inform treatment strategies and improve patient outcomes. Similarly, dPCR offers high sensitivity and specificity for detecting low-frequency SNPs and copy number variations, making it ideal for applications such as liquid biopsy, prenatal testing, and pathogen detection. These technological advancements are not only enhancing the capabilities of SNP genotyping and analysis but are also broadening its application scope, making it a versatile tool for both research and clinical applications.

What Factors Are Driving the Adoption of SNP Genotyping and Analysis Across Various Sectors and Regions?

The adoption of SNP genotyping and analysis is being driven by several key factors, including the increasing prevalence of genetic diseases, the growing demand for personalized medicine, and the rising focus on agricultural biotechnology. One of the primary drivers is the increasing prevalence of genetic diseases and the need for improved diagnostic and therapeutic solutions. As our understanding of the genetic basis of diseases continues to expand, there is a growing need for accurate and efficient methods of detecting genetic variations that contribute to disease susceptibility or drug response. SNP genotyping provides a valuable tool for identifying these variations, enabling researchers and clinicians to develop more effective diagnostic tests and therapeutic strategies. This trend is particularly strong in oncology, where SNP analysis is used to identify cancer-associated mutations, guide treatment decisions, and monitor disease progression.

Another significant factor driving the adoption of SNP genotyping is the growing demand for personalized medicine. Precision medicine aims to tailor treatments to individual patients based on their genetic, environmental, and lifestyle factors. SNP genotyping plays a critical role in this approach by providing insights into how genetic variations affect drug metabolism, efficacy, and safety. Pharmacogenomics, a key component of personalized medicine, uses SNP analysis to identify genetic markers that influence drug response, enabling clinicians to select the most appropriate treatment and dosage for each patient. This personalized approach not only improves treatment outcomes but also reduces the risk of adverse drug reactions, enhancing patient safety and satisfaction. The increasing use of SNP genotyping in pharmacogenomics is driving its adoption in healthcare settings, particularly in developed regions such as North America and Europe, where precision medicine initiatives are gaining momentum.

Moreover, the rising focus on agricultural biotechnology is influencing the adoption of SNP genotyping in crop and livestock breeding. In agriculture, SNP analysis is used to identify genetic markers associated with desirable traits such as disease resistance, drought tolerance, and high yield. By selecting for these markers, breeders can develop improved crop varieties and livestock breeds that are better suited to changing environmental conditions and market demands. SNP genotyping also plays a key role in plant and animal genomics research, where it is used to map genes, study genetic diversity, and understand the genetic basis of complex traits. This technology is helping to accelerate the development of sustainable agricultural practices and improve food security, particularly in regions such as Asia-Pacific and Latin America, where agriculture is a critical component of the economy. As these factors continue to shape the demand for genetic research and precision breeding, the adoption of SNP genotyping is expected to expand across various sectors and regions.

What Is Driving the Growth of the Global SNP Genotyping and Analysis Market?

The growth in the global SNP Genotyping and Analysis market is driven by several factors, including the increasing investment in genomic research, the rising incidence of genetic disorders, and advancements in genotyping technologies. One of the primary growth drivers is the increasing investment in genomic research by governments, academic institutions, and private companies. As the importance of genomics in understanding human health and disease continues to grow, there is a rising focus on funding projects and initiatives that aim to map genetic variations, identify disease-associated SNPs, and develop novel therapies. Major initiatives such as the Human Genome Project, the 1000 Genomes Project, and the UK Biobank have generated vast amounts of genetic data, providing a foundation for further research and driving the demand for advanced SNP genotyping and analysis tools. The growing availability of funding for genomics research is creating opportunities for market expansion, particularly in developed regions such as North America and Europe, where large-scale genomic studies are underway.

Another significant driver of market growth is the rising incidence of genetic disorders and the need for improved diagnostic and therapeutic solutions. Genetic disorders, such as cystic fibrosis, sickle cell anemia, and Huntington’s disease, are often caused by specific genetic variations that can be identified through SNP genotyping. As awareness of these conditions increases and diagnostic technologies improve, there is a growing demand for genetic testing services that can provide accurate and early diagnosis. SNP genotyping offers a reliable method for identifying genetic mutations and assessing disease risk, supporting its adoption in clinical settings. The increasing prevalence of genetic disorders is particularly pronounced in regions such as Asia-Pacific and the Middle East, where the demand for genetic testing and personalized medicine is growing rapidly.

Moreover, advancements in genotyping technologies are supporting the growth of the SNP genotyping and analysis market. The development of high-throughput platforms, such as NGS and microarrays, is enabling researchers to conduct large-scale genotyping studies at a lower cost and with higher accuracy. These technologies are also being used to develop new applications for SNP analysis, such as polygenic risk scores, which assess an individual’s genetic risk for common diseases based on the cumulative effect of multiple SNPs. The ability to perform high-throughput genotyping and analyze complex genetic data is expanding the scope of SNP genotyping beyond traditional applications, creating new opportunities for research and clinical use. Additionally, the increasing availability of commercial genotyping services and direct-to-consumer genetic testing kits is making SNP analysis more accessible to a wider audience, further driving market growth.

Furthermore, the growing emphasis on precision medicine and the integration of genomic data into clinical practice are influencing the growth of the SNP genotyping and analysis market. Precision medicine initiatives, such as the U.S. Precision Medicine Initiative and the European 1+ Million Genomes Initiative, are promoting the use of genetic data to inform clinical decision-making and improve patient outcomes. These initiatives are driving the adoption of SNP genotyping in healthcare settings, where it is used to guide treatment decisions, predict disease risk, and identify potential drug targets. As these factors continue to shape the global genomics landscape, the SNP Genotyping and Analysis market is expected to experience robust growth, driven by rising investment in research, technological advancements, and the increasing demand for personalized medicine and genetic testing solutions.

Select Competitors (Total 42 Featured) -

  • Affymetrix, Inc.
  • F. Hoffmann-La Roche AG
  • Fluidigm Corporation
  • Illumina, Inc.
  • Life Technologies Corporation
  • Sequenom, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • SNP Genotyping and Analysis - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Personalized Medicine Spurs Growth of SNP Genotyping and Analysis Market
    • Increased Use of SNP Genotyping in Disease Risk Assessment Expands Addressable Market
    • Focus on Enhancing Drug Development and Clinical Trials Fuels Market Demand for SNP Analysis
    • Rising Adoption of SNP Genotyping in Agricultural and Livestock Research Supports Market Expansion
    • Growing Use of SNP Analysis in Pharmacogenomics Strengthens Business Case for Market Growth
    • Rising Use of SNP Genotyping for Ancestry and Genetic Heritage Testing Fuels Market Demand
    • Increased Adoption of Next-Generation Sequencing (NGS) in SNP Genotyping Propels Market Growth
    • Rising Demand for SNP Genotyping in Population Genomics and Epidemiology Studies Supports Market Growth
    • Growing Use of SNP Genotyping in Oncology and Cancer Research Fuels Market Growth
    • Rising Use of SNP Genotyping in Animal Breeding and Conservation Genetics Sets the Stage for Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World SNP Genotyping and Analysis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for SNP Genotyping and Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for SNP Genotyping and Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for SNP Genotyping by Microarrays and GeneChips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for SNP Genotyping by Microarrays and GeneChips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for SNP Genotyping by Microarrays and GeneChips by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Taqman Allelic Discrimination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Taqman Allelic Discrimination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Taqman Allelic Discrimination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for SNP Pyrosequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for SNP Pyrosequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for SNP Pyrosequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Applied Biosciences SNPlex by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Applied Biosciences SNPlex by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Applied Biosciences SNPlex by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Sequenom MassARRAY MALDI-TOF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Sequenom MassARRAY MALDI-TOF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Sequenom MassARRAY MALDI-TOF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Diagnostic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Diagnostic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceuticals and Pharmacogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharmaceuticals and Pharmacogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pharmaceuticals and Pharmacogenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Agricultural Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Agricultural Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Agricultural Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Breeding and Animal Livestock by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Breeding and Animal Livestock by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Breeding and Animal Livestock by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • JAPAN
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • CHINA
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • EUROPE
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for SNP Genotyping and Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for SNP Genotyping and Analysis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • FRANCE
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • GERMANY
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030

IV. COMPETITION